new glp 1 agonist novo nordisk GLP-1 analogs, trend in obesity treatment, become even more effective < Pharma < Article Novo Nordisk justifies reasoning behind

Gut microbial dysbiosis in the irritable bowel syndrome: A systematic review and Meta-Analysis of Case-Control studies

The average Type 1 patient performs over 1,800 injections every year

Blue Cross announced Thursday that starting on January 1, 2026, standard coverage plans will not cover GLP-1s for weight loss

However, trial participants consistently lost weight while taking them, which prompted further research into their use for weight management

ISRN Inflamm

The exposition is substantiated by a collection of pertinent examples and an extensive array of references from both preclinical and clinical investigations